| Drug Type Fc fusion protein | 
| Synonyms engineered ACE-2-IgG1-Fc fusion protein targeting SARS-CoV-2 receptor-binding domain protein(Eutilex/Chonbuk National University), EU-129, EU129 | 
| Target | 
| Action- | 
| Mechanism SARS-CoV-2 S protein neutralization | 
| Therapeutic Areas | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| COVID-19 | Preclinical | South Korea  | 01 Jul 2021 | |
| Neoplasms | Preclinical | South Korea  | - | |
| Neoplasms | Preclinical | South Korea  | - | 






